Orchestra BioMed Holdings (OBIO) AI Stock Analysis

• Market Cap: $161.87M
• Dividend Yield: N/A
• Average Volume (3M): 341.08K
• Price to Earnings (P/E): ―
• Beta (1Y): 2.17
• Revenue Growth: 41.61%
• EPS Growth: -17.39%
• Country: US
• Employees: 70
• Sector: Healthcare
• Sector Strength: 47
• Industry: Biotechnology
• EPS (TTM): -0.50
• Shares Outstanding: 53,955,086
• 10 Day Avg. Volume: 318,279
• 30 Day Avg. Volume: 341,083
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 0.53
• Enterprise Value/Revenue: 28.98
• Enterprise Value/Gross Profit: 31.28
• Enterprise Value/Ebitda: -1.20
• 1Y Price Target: $3.00
• Price Target Upside: 5.63% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 1

• Rating: 48 Neutral
• Price Target: $3.00 ▲(5.63% Upside)

The overall score is primarily impacted by financial performance challenges, including high leverage and ongoing losses. The technical analysis suggests a bearish trend, while valuation metrics are weak due to negative earnings. However, the recent strategic capital infusion is a positive factor, reflecting confidence in the company's future potential.

Positive Factors

Funding and Investment

Ligand Pharmaceuticals will provide Orchestra BioMed with $20M in funding and purchase $5M of OBIO shares, with an additional $15M possible if milestones are met.

Strategic Partnerships

Orchestra BioMed announced new strategic partnerships with Ligand Pharmaceuticals and Medtronic, indicating potential growth opportunities.

Negative Factors

Commercial Partnership Uncertainty

A lack of certainty around the resolution of the Terumo Corporation partnership and whether OBIO will need to find a new commercial partner for the Virtue SAB program.

Equity Financing

The company's recent dilutive equity financing while maintaining its pace of spending reduces future profitability.

Financial Challenges

The company may need to raise additional capital within the next 12 months, indicating a potential financial challenge.

Orchestra BioMed Holdings Business Overview & Revenue Model

Company Description

Orchestra BioMed Holdings, Inc. operates as a biomedical innovation company. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension; and Virtue Sirolimus AngioInfusion Balloon (SAB) for the treatment of atherosclerotic artery disease. Its products also comprise FreeHold retractors that are minimally invasive surgical device solutions. The company has a strategic collaboration with Medtronic for the development and commercialization of BackBeat CNT for the treatment of hypertension in pacemaker-indicated patients; and a strategic partnership with Terumo Corporation for the development and commercialization of Virtue SAB for the treatment of artery disease. Orchestra BioMed Holdings, Inc. is based in New Hope, Pennsylvania.

How the Company Makes Money

Orchestra BioMed Holdings makes money primarily through the development and commercialization of its proprietary medical therapies and devices. The company's revenue model is based on partnerships and collaborations with established healthcare companies, where it licenses its technologies for further development and distribution. These partnerships often involve upfront payments, milestone payments, and royalties on sales of products developed using Orchestra BioMed's technologies. Additionally, the company may engage in direct sales of its products, once approved, to healthcare providers and institutions. Significant partnerships with leading medical device and biopharmaceutical companies contribute to its earnings by leveraging their distribution networks and regulatory expertise to bring products to market efficiently.

Orchestra BioMed Holdings Financial Statement Overview

Summary

Orchestra BioMed Holdings is facing significant financial challenges, with negative net profit margins and cash flows. While the company has a strong gross profit margin and manageable debt levels, its ongoing losses and negative cash flows are critical concerns that need immediate attention.

Income Statement

Orchestra BioMed Holdings has faced significant challenges in improving its profitability. The TTM Gross Profit Margin is strong at 92.61%, but the Net Profit Margin is deeply negative at -229.78%, reflecting substantial losses. Revenue has seen a slight growth of 9.39% compared to the previous year, but EBIT and EBITDA margins remain concerningly negative at -238.33% and -237.66%, respectively. The company has struggled with high operating losses, impacting its overall financial health.

Balance Sheet

The company's balance sheet indicates a moderate degree of financial risk. The Debt-to-Equity Ratio is relatively low at 0.12, suggesting manageable debt levels. However, the Return on Equity is negative, driven by ongoing net losses, and the Equity Ratio is 28.55%, indicating a moderate reliance on liabilities for financing. The company's equity position has weakened over time, reflecting sustained losses.

Cash Flow

Orchestra BioMed Holdings exhibits a strained cash flow position. The Free Cash Flow is significantly negative at -$54.45 million TTM, with a notable decline in Free Cash Flow compared to the previous year. The Operating Cash Flow to Net Income Ratio is 0.81, indicating that the company is not generating sufficient operating cash to cover its net losses. The company needs to improve its cash generation capabilities to sustain operations.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	2.94M	2.64M	2.76M	3.53M	-782.00K	5.70M
Gross Profit	2.73M	2.43M	2.57M	3.21M	-981.00K	5.56M
EBITDA	-71.11M	-64.30M	-51.22M	-32.44M	-21.62M	-18.61M
Net Income	-69.70M	-61.02M	-49.12M	-33.61M	-23.01M	-21.36M
Balance Sheet
Total Assets	42.83M	76.17M	95.21M	95.57M	13.53M	38.09M
Cash, Cash Equivalents and Short-Term Investments	33.92M	66.81M	87.59M	83.78M	10.90M	35.79M
Total Debt	1.97M	16.53M	1.69M	11.87M	5.67M	9.46M
Total Liabilities	42.53M	43.22M	27.17M	43.04M	84.76M	86.63M
Stockholders Equity	295.00K	32.96M	68.04M	52.53M	-71.23M	-48.54M
Cash Flow
Free Cash Flow	-59.70M	-50.85M	-46.20M	-29.88M	-19.70M	-26.72M
Operating Cash Flow	-59.38M	-50.56M	-46.13M	-29.29M	-19.43M	-26.18M
Investing Cash Flow	26.16M	13.09M	10.69M	-64.12M	13.02M	26.97M
Financing Cash Flow	28.26M	29.17M	46.22M	103.26M	-3.99M	10.00M

Orchestra BioMed Holdings Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 2.84
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For OBIO, the sentiment is Neutral. The current price of 2.84 is above the 20-day moving average (MA) of 2.65, below the 50-day MA of 2.89, and below the 200-day MA of 3.97, indicating a neutral trend. The MACD of -0.06 indicates Negative momentum. The RSI at 52.66 is Neutral, neither overbought nor oversold. The STOCH value of 71.87 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for OBIO.

Orchestra BioMed Holdings Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
NKTR	56 Neutral	$547.35M	―	-440.80%	―	-19.56%	35.55%
Sector *	51 Neutral	$7.83B	-0.18	-40.10%	2.29%	21.46%	-2.03%
LRMR	49 Neutral	$320.35M	―	-60.25%	―	―	-40.03%
OBIO	48 Neutral	$161.87M	―	-313.82%	―	41.61%	-17.39%
RAPT	39 Underperform	$186.63M	―	-77.83%	―	―	43.16%
ALDX	37 Underperform	$352.79M	―	-65.91%	―	―	-32.74%
KOD	35 Underperform	$511.31M	―	-140.33%	―	―	-0.69%

Orchestra BioMed Holdings Corporate Events

Orchestra BioMed Holdings Closes $40M Public Offering

On August 1, 2025, Orchestra BioMed Holdings announced the pricing of its underwritten public offering, which included 9,413,637 shares of common stock and pre-funded warrants, raising approximately $40 million. The proceeds will support the company’s atrioventricular interval modulation therapy program, the BACKBEAT study, the Virtue SAB program, and other research and development initiatives. The offering closed on August 4, 2025, and was part of a broader strategy to advance its cardiovascular care technologies.

Orchestra BioMed Secures $70M for Cardiology Programs

On July 31, 2025, Orchestra BioMed Holdings announced securing $70 million in strategic capital from Ligand Pharmaceuticals and Medtronic to advance its late-stage cardiology programs. This investment includes Ligand’s $40 million commitment and Medtronic’s $30 million, reflecting confidence in Orchestra BioMed’s clinical progress and potential. The collaboration with Medtronic has been expanded to potentially integrate AVIM therapy into leadless pacemaker technology, aiming to transform care for patients with uncontrolled hypertension. This financial backing and strategic alignment are expected to support Orchestra BioMed in achieving key milestones in its high-impact clinical programs, addressing significant unmet medical needs in global markets.

Orchestra BioMed Confirms Director Elections and Auditor

On June 24, 2025, Orchestra BioMed Holdings, Inc. held its Annual Meeting of Stockholders, where stockholders voted on two key proposals. The election of three Class II directors, Chris Cleary, Pamela Connealy, and David Pacitti, was confirmed, and the appointment of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025, was ratified.